Trubion Pharmaceuticals, Inc. (NASDAQ: TRBN) shot way up in pre-market trading preceding the company’s acquisition by Emergent Biosolutions Inc. (NYSE: EBS). At the 8:35 AM EST Trubion is up 49.67% from $3 to $4.49 during a 52-week range of 2.29 – 6.75. The company has also already traded 3,000 shares, a significant figured compared with their average of 16,011.
The transaftion, if it is completed, will provide Trubion shareholders with $1.365 in cash, as well as 0.1641 shares of Emergent common stock for each share of Trubion they currently possess.
-Michael B. Sauter